NVCR NovoCure Ltd

Price (delayed)

$120.74

Market cap

$12.51B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.04

Enterprise value

$12.73B

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating ...

Highlights
The company's quick ratio has surged by 62% YoY
The equity has increased by 48% year-on-year and by 7% since the previous quarter
The net income has plunged by 139% from the previous quarter and by 139% YoY
NVCR's EPS has dropped by 133% since the previous quarter and by 131% year-on-year

Key stats

What are the main financial stats of NVCR
Market
Shares outstanding
103.65M
Market cap
$12.51B
Enterprise value
$12.73B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
31.43
Price to sales (P/S)
22.93
EV/EBIT
863.92
EV/EBITDA
524.97
EV/Sales
23.36
Earnings
Revenue
$544.83M
EBIT
$14.73M
EBITDA
$24.24M
Free cash flow
$113.26M
Per share
EPS
-$0.04
Free cash flow per share
$1.09
Book value per share
$3.84
Revenue per share
$5.26
TBVPS
$10.6
Balance sheet
Total assets
$1.1B
Total liabilities
$699.79M
Debt
$572.51M
Equity
$397.27M
Working capital
$929.36M
Liquidity
Debt to equity
1.44
Current ratio
9
Quick ratio
8.77
Net debt/EBITDA
8.74
Margins
EBITDA margin
4.4%
Gross margin
79.5%
Net margin
-0.8%
Operating margin
2.7%
Efficiency
Return on assets
-0.5%
Return on equity
-1.2%
Return on invested capital
1.6%
Return on capital employed
1.5%
Return on sales
2.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NVCR stock price

How has the NovoCure stock price performed over time
Intraday
-1.02%
1 week
7.59%
1 month
-7.92%
1 year
-3.44%
YTD
-30.22%
QTD
3.93%

Financial performance

How have NovoCure's revenue and profit performed over time
Revenue
$544.83M
Gross profit
$433.31M
Operating income
$14.73M
Net income
-$4.57M
Gross margin
79.5%
Net margin
-0.8%
The net income has plunged by 139% from the previous quarter and by 139% YoY
NovoCure's net margin has plunged by 136% from the previous quarter and by 128% YoY
NovoCure's operating income has surged by 102% YoY but it has shrunk by 56% QoQ
NovoCure's operating margin has shrunk by 58% QoQ but it has surged by 50% YoY

Growth

What is NovoCure's growth rate over time

Valuation

What is NovoCure stock price valuation
P/E
N/A
P/B
31.43
P/S
22.93
EV/EBIT
863.92
EV/EBITDA
524.97
EV/Sales
23.36
NVCR's EPS has dropped by 133% since the previous quarter and by 131% year-on-year
The equity has increased by 48% year-on-year and by 7% since the previous quarter
The price to book (P/B) is 25% lower than the last 4 quarters average of 41.9 but 11% higher than the 5-year quarterly average of 28.3
The company's revenue rose by 33% YoY and by 3.3% QoQ
NVCR's price to sales (P/S) is 29% lower than its last 4 quarters average of 32.1 but 25% higher than its 5-year quarterly average of 18.4

Efficiency

How efficient is NovoCure business performance
NovoCure's return on equity has shrunk by 136% QoQ and by 124% YoY
The company's return on assets has shrunk by 133% QoQ and by 121% YoY
NovoCure's ROIC has plunged by 66% from the previous quarter and by 16% YoY
NVCR's return on sales has dropped by 58% since the previous quarter but it has surged by 50% year-on-year

Dividends

What is NVCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVCR.

Financial health

How did NovoCure financials performed over time
NovoCure's total assets is 57% more than its total liabilities
NovoCure's total liabilities has surged by 168% YoY
NovoCure's total assets has soared by 107% YoY and by 2.8% from the previous quarter
NovoCure's debt is 44% more than its equity
NVCR's debt to equity has soared by 136% YoY but it is down by 6% QoQ
The equity has increased by 48% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.